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Abstract
Background: A complete pathological response to neo-adjuvant chemo-radiation for oesophageal
cancer is associated with favourable survival. However, such a benefit is seen in the minority. If one
could identify, at diagnosis, those patients who were unlikely to respond unnecessary toxicity could
be avoided and alternative treatment can be considered. The aim of this review was to highlight
predictive markers currently assessed and evaluate their clinical utility.
Methods: A systematic search of Pubmed and Google Scholar was performed using the following
keywords; "neo-adjuvant", "oesophageal", "trimodality", "chemotherapy", "radiotherapy",
"chemoradiation" and "predict". The original manuscripts were sourced for further articles of
relevance.
Results: Conventional indices including tumour stage and grade seem unable to predict histological
response. Immuno-histochemical markers have been extensively studied, but none has made its
way into routine clinical practice. Global gene expression from fresh pre-treatment tissue using
cDNA microarray has only recently been assessed, but shows considerable promise. Molecular
imaging using FDG-PET seems to be able to predict response after neo-adjuvant chemoradiation
has finished, but there is a paucity of data when such imaging is performed earlier.
Conclusion: Currently there are no clinically useful predictors of response based on standard
pathological assessment and immunohistochemistry. Genomics, proteomics and molecular imaging
may hold promise.
Background
Cancer medicine is in the midst of a technological revolu-
tion and the way the disease is managed is undergoing
enormous change. For the very first time it is becoming
increasingly possible to individualise a patient's treatment
by predicting those that will and those that will not
respond to a chosen therapy. This is being achieved
through rapid developments in both advanced diagnostic
imaging and translational medicine. Clinical trials incor-
porating expression array data are already underway in
some of the more common tumour sites, such as breast
cancer [1]. As a result the foundations have been laid for
some of the less frequent, but by no means less serious,
pathological types.
Oesophageal cancer is the eighth most common cancer
worldwide and more than 80% of cancers occur in less
developed countries [2]. The incidence in Europe is 5.4
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100,000 per year. Survival correlates with stage of disease.
Five-year survival rates range from 40 to 62 percent for
patients treated for localized cancer (stage I and IIA), and
from 18 to 25 percent for those with involvement of
regional nodes (stage IIB and III) [3]. According to data
from the National Cancer Institute Surveillance, Epidemi-
ology and End Results (SEER) Program, the five-year sur-
vival rate for all patients with oesophageal cancer has
improved modestly over the last 30 years, from 5 percent
in the years 1974 to 1976, to 13 percent during the period
1992 to 1998 [4]. These dismal figures are indicative of
the advanced stage of disease (local-regional or meta-
static, stages IIB, III and IV) at diagnosis in most individu-
als [4].
Although the incidence of squamous cell carcinoma has
been declining over the past two decades, the incidence of
adenocarcinoma has increased markedly. In the US aden-
ocarcinoma now accounts for more than 50% of oesopha-
geal cancer cases [5]. The high mortality rate reflects early
lymphatic and haematogenous spread as well as the lack
of effective treatments and early therapeutic options.
For many years the standard therapy for localised
oesophageal carcinoma has been surgical resection [6].
However local control and overall survival remain poor,
and even after radical resection and lymphadenectomy
the 5-year survival is at best approximately 40 percent
[7,8]. In an effort to improve these figures the manage-
ment of local-regional oesophageal cancer has undergone
a major evolution over the past 15 years. Numerous strat-
egies employing various pre- and post-operative therapies
have been studied as well as trials where surgery has been
omitted altogether.
To date the optimal therapy for potentially resectable
oesophageal cancer remains unclear.
Although somewhat controversial, the use of neo-adju-
vant chemoradiation (CRT) has increased outside of clin-
ical trials, and the Patterns of Care studies in the US
showed that preoperative CRT therapy increased from
10.4% during 1992–1994 to 26.6% in 1996–1999 for
patients with stage IIb and III oesophageal cancer [9]. The
same is now true in many European Centres.
However, many patients do not benefit from such an
approach and there are now evolving strategies to identify
predictive response markers. Several analyses suggest that
it is the response to preoperative therapy (particularly the
absence of residual disease (pCR) in the surgical speci-
men) that best predicts disease-free and overall survival
[10]. A pCR occurs in approximately 15–30% of cases,
and three-year survival rates of approximately 60% irre-
spective of the applied protocol, type of histology and
tumour stage are achieved [10]. A further subdivision of
pathological response to neoadjuvant regimens, the
tumour regression grade (TRG), may also identify patterns
of incomplete response that may impact on treatment
outcome [11]. Regression grading stratifies response
based on the biological effect of radiation on tumours,
dividing it into 5 different grades based on the ratio of
fibrosis to tumour (Figure 1). Mandard described com-
plete response as histologic fibrosis with or without
inflammation extending through the different layers of
the oesophageal wall, but with no viable residual tumour
cells (tumour regression grade (TRG) 1). Subtotal
response (TRG 2) was characterized by the presence of
rare residual cancer cells scattered through the fibrosis. An
increase in the number of residual cancer cells, but with
fibrosis predominating was termed a partial response
(TRG 3). Minimal remission (TRG 4) showed residual
cancer outgrowing fibrosis. Absence of any regressive
changes (TRG 5) defined no change.
The addition of the pathological response to standard
pTNM has been recently advocated [12]. Where a cohort
of patients may benefit from neoadjuvant CRT, with pCR
and TRG the surrogate markers, many patients will not be
helped, and their prognosis may be worsened by delay in
surgery and by the added risks of surgery in patients on
multimodal protocols. A predictor of response or resist-
ance based on pre-treatment demographics, imaging, his-
tolopathologic, molecular, or genetic information would
have potentially enormous application in optimising out-
comes and in the design of clinical trials. However,
despite numerous studies to date no clear candidate mark-
ers that predict pathological response have emerged.
Predicting response
Conventional patient and histological indices
Numerous clinical and pathological parameters have
been analysed in a small number of oesophageal cancer
studies with regard to their utility in the prediction of the
response to pre-operative CRT. Mandard found that the
larger the initial primary tumour the poorer the overall
response to neo-adjuvant treatment [11]. Pre-treatment
performance status, primary location and age are clearly
important factors in terms of tolerating therapy, but they
are not known to be associated with the pathological
response [13].
Other pre-therapy parameters that some have identified as
potentially useful include the patient's nutritional status
[14], tumour cell aneuploidy [15] and tumour differenti-
ation [16].
In general, however, many of these factors tend to be rel-
atively crude determinants of the overall managementPage 2 of 11
(page number not for citation purposes)
World Journal of Surgical Oncology 2007, 5:97 http://www.wjso.com/content/5/1/97approach, i.e. curative or palliative, rather than being pre-
dictors of the molecular response to treatment. It would
seem that it is the post-therapy pathological stage that best
predicts the survival of patients who receive neo-adjuvant
CRT [13] and more precise markers are required in order
to determine the most appropriate therapeutic strategy.
Tissue markers
Most studies have correlated the expression of molecular
markers in the pre-treatment biopsy with either the bio-
logical response to treatment in the oesophagectomy
specimen or to survival/recurrence data following treat-
ment.




The p53 gene is one of the most widely investigated in
human cancer, including oesophageal. Several groups
have found that the protein it encodes is one of the prog-
nostic indicators in various cancers [17,18]. It is one of the
genes responsible for repairing a damaged cells' DNA or
triggering apoptosis when this cannot occur (Figure
2[19]) and it is generally accepted that it may be intrinsi-
cally involved in the response to CRT [20,21]. Several tri-
als have studied p53 expression as a determinant of
response to chemotherapy with or without radiotherapy
in oesophageal cancer. In oesophageal adenocarcinoma
Duhaylongsod immunostained 42 patients for p53 and c-
erb B2 protein. All patients received neoadjuvant CRT fol-
lowed by resection [22]. They found that 84% of the p53
positive tumours had residual disease as opposed to 44%
of the p53 negative (p = 0.01). Similarly in patients with
squamous cell carcinoma Seitz et al., identified immuno-
histochemically a significant association between p53
overexpression and a lower complete response [15]. To
counter these results other groups have found no such an
association [23]. It may be the small sample sizes or the
differences in immunohistochemical staining methods
that explain these discrepancies. Equally it has been pos-
tulated that p53 overexpression is not necessarily synony-
mous with p53 mutations [24]. Furthermore absence of
p53 staining may occur with gene deletion, failure of tran-
scription, or a non-stabilizing mutation, all of which may
be associated with loss of p53 function [25].
Pathological response grading following neoadjuvant chemoradiation in oesophageal cancer (Mandard [11])Figure 1
Pathological response grading following neoadjuvant chemoradiation in oesophageal cancer (Mandard [11]).Page 3 of 11
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The p21 protein is a key member of the p53 signalling
pathway (figure 2). It is transcriptionally activated by p53
following DNA damage by ionising radiation, which in
turn causes cell cycle arrest, and apoptosis [26,27]. It has
been studied as a response predictor because it disrupts
regulatory networks, in particular those involved in cell
death signaling. It may therefore be a causative factor of
radioresistance.
Nakamura et al., found that the survival of patients with
p21 positive oesophageal tumours treated with definitive
CRT was significantly better than those where no such
expression existed (p = 0.0013) [28]. They also identified
that the survival of those patients with p53 negative
tumours was significantly higher if they were p21 positive
than negative (P = 0.0452).
Conversely another Japanese group found that whilst p21
positive expression in the absence of p53 was associated
with favourable effects from preoperative chemotherapy
there was no such correlation between p21 expression and
the clinical effects following CRT [29,30].
Survivin
Survivin is a member of the inhibitor of apoptosis family
and is known to be involved in resistance to chemo- and
radiation therapy. It is expressed in several cancers partic-
ularly rectal cancer where it's expression is associated with
a poor survival following CRT [31]. In oesophageal cancer
Kato et al., found that that high survivin expression pre-
dicted a significantly reduced median survival (9.0 vs 30.0
months, p = 0.0023) in patients receiving pre-operative
chemotherapy [32]. Conversely other groups have found
the reverse. In tissue samples taken from patients prior to
CRT elevated tumour:normal levels of survivin mRNA
were significantly associated with improved survival but
not histological regression [33].
Cyclo-oxygenase-2 (COX-2)
COX-2 plays an important role in prostaglandin synthesis
and mediates angiogenesis and tumour growth. It is over-
expressed in various human malignancies and is an
important mediator of tumour invasiveness and metasta-
sis [34]. In addition, clinical studies in nasopharyngeal
[35] and cervical.
Cancer [36] have demonstrated that endogenous COX 2
expression in pre-treatment biopsies are indicative of a
poor response to and an unfavourable prognosis follow-
ing chemotherapy and ionising radiation and chemother-
apy. There is similar data in oesophageal cancer. In 29
biopsies taken from squamous cell carcinoma patients
who went on to receive CRT high Cox-2 mRNA levels were
significantly associated with a poor response to treatment
(p < 0.05) [37]. Whilst Cox-2 levels have not been corre-
lated with response to neoadjuvant CRT in oesophageal
adenocarcinoma there is a wealth of literature showing
that high levels of expression in this subtype are associ-
ated with aggressive disease and a poor survival [38].
Tumour hypoxia
Hypoxic regions within tumours may lead to chemo- and
radioresistance by depriving cells of oxygen necessary for
the cytotoxic activities of these agents [39]. Furthermore,
tumour hypoxia promotes up-regulation of angiogenic
and tumour cell survival factors resulting in increased pro-
liferation, radioresistance and angiogenesis. Angiogenesis
has an important role in solid tumour growth and metas-
tasis [40]. Vascular endothelial cell growth factor (VEGF)
is the main angiogenic factor known to be involved in
pathological angiogenesis. Its induction in several solid
tumours is thought to be important with respect to the
chemotherapy and radiotherapy response [41]. In one
study CRT was administered to 52 patients with oesopha-
geal squamous cell carcinoma [42]. Expression of p53,
thymidine phosphorylase and VEGF was analysed by
Flow diagram of the P53/apoptosis pathwayigure 2
Flow diagram of the P53/apoptosis pathway. Constituents of 
this pathway are the most commonly assessed predictive 
markers in oesophageal cancer [19].Page 4 of 11
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radical surgery and from these multivariate analysis iden-
tified that only VEGF was a significant prognostic indica-
tor (p = 0.0147). Its expression was associated with a high
incidence of treatment failure and a significantly worse 5-
year survival rate (p = 0.037). These results are further sup-
ported by Gorski et al., who found that the anti-tumour
effects of ionizing radiation could be enhanced if VEGF
activity was blocked [43]. It remains unclear, however, as
to whether the expression of VEGF by itself directly or
indirectly determines whether a tumour responds to CRT
[44].
Growth regulation
Epidermal growth factor receptor (EGFR)
Aberrant activation of the epidermal growth factor recep-
tor (EGFR) is frequently observed in neoplasia, notably in
tumours of epithelial origin. In squamous cell oesopha-
geal carcinoma Hickey et al., compared tumour response
with expression of EGFR and proliferating cell nuclear
antigen [45]. There was a significant survival advantage in
those staining negative for one or both markers, while
those which stained positive responded poorly. The same
would appear to be true for oesophageal adenocarcinoma.
Not only was EGFR expression associated with a higher
TNM stage, but also with shorter disease-free and overall
survival [46].
HER-2
HER-2 protein is a 185 kD transmembrane protein and a
member of the EGFR family. It is a proto-oncogene that
encodes a tyrosine kinase growth factor receptor and has
been associated with the pathogenesis of several human
cancers. Its over-expression in breast cancer is associated
with a poorer prognosis [47]. In oesophageal cancer the
data is conflicting. In adenocarcinoma Duhaylongsod et
al., found that over-expression predicted a favourable
response to CRT and a 5 year actuarial survival of 60%
[22]. However, other groups have found that over-expres-
sion in this sub-type was associated with a poor prognosis
[48]. In squamous cell carcinoma Akamatsu et al., how-
ever, found that immunostaining was useful for predict-
ing chemoradioresistance but this did not correlate with
survival [49].
Cyclins
The cyclins are important oncogenic proteins and regula-
tors of the cell cycle.
Sarbia et al., assessed cyclin D1 expression by immuno-
histochemistry in squamous cell oesophageal cancer [50].
They identified that in patients treated with multi-modal
therapy cyclin D1 expression correlated with a poor
response to treatment but not to overall survival. Cyclin E
is reportedly overexpressed in adenocarcinoma of the dis-
tal oesophagus and in gastric cancer is associated with
reduced survival [51]. In oesophageal cancer, however, its
prognostic effect has not been elucidated.
Markers of resistance to commonly used chemotherapy 
agents
Platinum-based compounds, 5-fluorouracil and taxanes
are the agents most commonly used in the treatment of
oesophageal cancer and advances in molecular pharma-
cology have enhanced our understanding of their mecha-
nisms of action and modes of resistance.
Joshi et al., measured gene expressions of thymidylate syn-
thase 1 (TS1), glutathione S-transferase π (GSTP1), and
excision cross-complementing gene 1 (ERCC1) by quanti-
tative RT-PCR in the pre-treatment biopsies of tumour tis-
sue specimens taken from patients scheduled to receive
neoadjuvant 5-FU, cisplatin and radiotherapy. Elevated
expression of these genes was significantly associated with
a poor survival (p = 0.007) [52].
Metallothionein (MT)
MT is a small protein with a high affinity for divalent
heavy metal ions. It is involved in many patho-physiolog-
ical processes, like metal homeostasis and detoxification,
cell proliferation, apoptosis, therapy resistance, and pro-
tection against oxidative damage. Alterations in the
immuno-histochemical expression of MT have been
reported for various human tumours, and a high expres-
sion has been found to be associated with a poor clinical
outcome [53]. Much of the work in squamous cell
oesophageal cancer comes from Japan. MT-positivity in
patients treated with neoadjuvant chemotherapy with or
without radiotherapy has usually been associated with a
worse prognosis [54]. Some studies have, however, shown
no such association [55]. There is no data on the effects of
MT-positivity and the response to treatment in oesopha-
geal adenocarcinoma, but it is implicated in the malig-
nant transformation of Barrett's epithelium [56].
Nuclear factor-kappa B (NF-KB)
NF-KB regulates several genes involved in inflammatory,
immune and apoptotic responses. In patients treated with
neoadjuvant CRT for oesophageal adenocarcinoma
Abdel-Latif et al., identified that its' expression was
inversely related to a major or complete pathological
response. 75% of those that did not respond were NFKB
negative, whilst only 18% of the responders were positive
(p < 0.00001) [57]. More recently Izzo et al., found that
activated NF-KB expression was significantly associated
with residual disease following neo-adjuvant CRT (p =
0.006), metastatic progression (p = 0.01) and reduced sur-
vival (p = 0.01) in 80 oesophageal cancer patients [58].Page 5 of 11
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Serum markers have not proved particularly useful in pre-
dicting the response of oesophageal cancer to neo-adju-
vant therapy.
Kim et al., evaluated serial CEA levels in 90 patients with
potentially resectable oesophageal and gastric adenocarci-
noma treated with preoperative chemotherapy [59].
Measurements were taken before treatment and serially
thereafter. An increasing CEA level predicted relapse and
correlated well with visceral involvement and clinical
responses correlated with declining levels of CEA. How-
ever, the levels did not predict resectability or survival.
Another group analysed serum VEGF levels in patients
with oesophageal cancer before, during and after CRT.
Levels did not decline during therapy. They fell following
resection but then rose to pre-operative values before fall-
ing to normal at three months. They postulated that the
tumours were not generating VEGF and therefore levels
could not be used as response markers [60].
Quillien et al., examined the serum markers CYFRA 21-1,
TPA and SCC in 96 patients with squamous cell oesopha-
geal carcinoma. CYFRA 21-1 was the only marker whose
pre-treatment levels significantly correlated with patho-
logical response, but on multivariate analysis treatment
was the only independent factor [61].
Nakamura et al., assessed the clinical value of CYFRA 21-
1 in comparison to SCC-Ag, CEA and CA19-9 in 112
patients with squamous cell carcinoma. Levels of CYFRA
21-1 correlated closely with stage and with clinical
response to both chemotherapy and CRT [62].
These reports suggest that CYFRA 21-1 may be the most
useful serum marker currently available, but this has not
become widely adopted.
Gene expression arrays
Patients diagnosed with the same stage of cancer by con-
ventional clinical and histopathological criteria may have
a completely different course of disease. Since cancer is
fundamentally a malfunction of gene expression giving
rise to aberrant malignant growth, the most direct classifi-
cation approach would be to analyse gene expression pat-
terns. To find the relatively small number of genes that are
characteristically de-regulated in a given cancer cell,
among thousands of genes that are normally expressed,
requires high-throughput technologies and sophisticated
computational tools.
The first high density microarrays were developed to ana-
lyse gene expression by quantitating thousands of mRNAs
present in a cell or tissue sample (DNA arrays). Other
microarray approaches include the quantitation of pro-
teins (protein arrays), or the analysis of a large number of
tissue samples in parallel (tissue arrays). It was clear early
on that arrays could be very useful tools in molecular pro-
filing of cancer cells, thus revealing information that can-
not be obtained by traditional histological assessment
[63].
Over the last few years there have been numerous gene
expression studies that have enhanced our understanding
of the biology of oesophageal cancer [64-70]. It was
hoped that these might identify potential biomarkers for
therapeutic targeting, but none of them specifically
addressed treatment and pathological outcome data and
so their clinical value is so far limited.
There has, however, been only one clinically relevant
study. The MD Anderson performed gene expression anal-
yses on 19 patients prior to neo-adjuvant CRT and corre-
lated their findings with the final histopathological
response [71]. Unsupervised hierarchical cluster analysis
of the cancer biopsies segregated them in to two molecu-
lar subtypes. Amongst the adenocarcinomas, most that
achieved a complete response clustered in one group and
all but one of the poorer responders in the other. They
identified a number of genes that were differentially
expressed between the two molecular sub-types, several of
which have been reported to occur in oesophageal cancer.
The authors stress that this was a preliminary study and
clearly larger sample numbers and stringent validation is
essential before the data generated from array experiments
can be evaluated in clinical trials.
Imaging
Despite their widespread use in primary staging, conven-
tional computed tomography (CT) and endoscopic ultra-
sound (EUS) have not proven beneficial in predicting the
response of oesophageal tumours to CRT [72,73]. With
the advent of molecular imaging, which has demonstrated
superiority over conventional imaging techniques at diag-
nosis, FDG-PET (18fluorodeoxyglucose positron emission
tomography) is frequently being used to predict response
in several malignancies [74,75].
Alterations in tissue metabolism often precede anatomi-
cal changes and this forms the basis of FDG-PET scanning.
In 22 patients with advanced breast cancer, changes in
FDG uptake were able to predict the eventual histopatho-
logic response with an accuracy of 88% after the first
course of drugs and 91% after the second course [76].
Similar utility has been described in cancers of the lung
[77] and colon [78], as well as Hodgkin's [79] and non-
Hodgkin's lymphoma [80].Page 6 of 11
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Studies evaluating tumour response with PET during and
at the completion of neo-adjuvant therapy have yielded
encouraging results (Table 1). These studies suggest that
changes in FDG uptake in response to therapy correlate
with the pathological response as well as predict the risk
of local recurrence and survival. Squamous cell oesopha-
geal cancer is more frequently treated with neoadjuvant
CRT. Studies have therefore been performed in either
squamous cell carcinoma exclusively or in a combination
of the two tumour types. There have been no studies
investigating the predictive role of FDG-PET in oesopha-
geal adenocarcinoma exclusively and consequently it is
not possible to ascertain the usefulness of molecular
imaging in predicting response to CRT in one subtype
over another.
Levine et al., performed an FDG-PET at diagnosis and fol-
lowing CRT in 31 oesophageal cancer patients [81]. They
found that the standardized uptake value (SUV) decreased
significantly more in those patients who responded (path-
ological complete response or microscopic residual dis-
ease) than in those who did not (p = 0.05). The MD
Anderson study performed CT, EUS and PET before and
after CRT in 73 adenocarcinoma and 10 squamous cell
carcinoma patients [73]. They found that PET most accu-
rately predicted long-term survival and that by uni- and
multivariate Cox regression analysis an SUV ≥4 had the
greatest accuracy in predicting pathological response.
Similarly there is some evidence to suggest that the initial
SUV may be predictive of outcome. Levine's group found
that an SUV at diagnosis ≥15 was associated with an
observed 77.8% significant response (pathological com-
plete response or microscopic residual disease) compared
with 24.2% for patients with a pretreatment SUV < 15 (P
= 0.005).
In the majority of studies to date the second PET has been
performed after the neo-adjuvant phase of treatment [81-
89]. Earlier response prediction, by repeating the PET dur-
ing neoadjuvant therapy, could potentially differentiate
responders from non-responders, minimise the inherent
toxicity associated with current regimens and direct non-
responders towards alternative therapies. Only two such
studies have been performed [90,91]. Wieder et al.,
reported pre-therapy and early repeat FDG-PET scans at 2
weeks (of a four week neo-adjuvant CRT regime) in 27
patients with squamous cell carcinoma of the oesopha-
gus, a treatment regimen similar to that which was used in
the Gillham et al., study. In the former, the change in SUV
following CRT reliably separated responders and non-
responders; using a reduction in SUV of 30% as the opti-
mal cut off point, they identified a sensitivity and specifi-
city of 93% and 88% respectively with a satisfactory
accuracy of 79%. In the latter study the second PET scan
was performed after only one week of CRT and included
both squamous cell and adenocarcinoma sub-types.
Changes in FDG uptake failed to predict the pathological
response. Both studies were small and are not directly
comparable. However the inflammatory effect of ionising
radiation on oesophageal tissue may interfere with the
interpretation of the second PET scan.
Future
For many years formalin fixed paraffin embedded tissue
samples have provided a wealth of information using
immuno-histochemical and DNA based techniques. The
process is relatively straightforward and inexpensive and
the material can be stored for a number of years. A
number of different markers have been identified that
seem to be associated with a good or a poor response to
treatment in oesophageal cancer. However, comparing
the results of different studies is markedly hampered by
the differing individual techniques and batch-to-batch
variability [92]. As a result none of them have found their
way into routine clinical use. Some of these issues may be
overcome by the use of tissue microarrays, but such an
approach remains very much in its infancy until the
appropriate candidate markers are identified.
Advances in microarray technology may mean that, by
assessing the transcriptional activity of a large number of
genes, the complex gene expression profile may contain
more information than any individual molecule that con-
tributes to it. A number of studies have used such an
approach to study the different profiles between oesopha-
geal cancer and its pre-malignant components. Unlike in
other tumour sites only one study has specifically
addressed the issue of response prediction to CRT in
oesophageal cancer [71].
The other area of translational medicine that holds prom-
ise is that of serum proteomics. It is based on the assump-
tion that cancers shed protein debris into the
bloodstream. The technique has been used to differentiate
benign from malignant disease [93-95] but, to date, has
not been applied in the area of response prediction.
Conclusion
The management of patients with localised oesophageal
cancer would be greatly enhanced if predictors of
response could be identified.
It would seem there is little to be gained by studying con-
ventional patient and histological indices. At present
none of the tissue or serum markers of response to neo-
adjuvant treatment are sufficiently accurate on their own
to be used to predict response in an individual patient.
Genomics and proteomics are fast generating vast
amounts of data. In time, it seems likely that these mayPage 7 of 11
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Table 1: Studies that have assessed the role of FDG-PET in predicting the response of oesophageal cancer to neoadjuvant 
chemoradiation
Study + Reference Path Chemo Radiotherapy Second PET Main Results
Brucher et al, 2001 [82] 24 SCC 5 FU 30 Gy/15# 3 weeks after CRT An SUV reduction of 
>52% led to sensitivity, 
specificity, positive and 
negative predictive 
values of 100%, 55%, 
72% and 100% 
respectively
Kato et al, 2002 [83] 10 SCC cis/5 FU 40 Gy/20# 2 weeks after CRT Pathological response 
did not correlate with 
rate of reduction of 
SUV
Arslan et al, 2002 [84] 22 AD
2 SCC
See notes‡ 40–50.4 Gy/20–28# 4 wks after CRT Change in volume 
identified responders. 
Quantitative evaluation 
of primary tumour pre 
and post therapy could 
not separate post 
therapy inflammation 
from residual tumour
Flamen et al, 2002 [85] 27 SCC
9 AD
cis/5 FU 40 Gy/20# 4–6 weeks after CRT When >80% reduction 
in FDG tumour:liver 
uptake ratios used to 
define response 
sensitivity 71% and 
specificity 82%
Downey et al, 2003 [86] 26 AD
13 SCC
cis/taxol 50.4 Gy/28# (2 had no RT) After CRT (not specified) SUV reduction >60% 
associated with non-
significant disease-free 
and survival advantage 
compared to when 
reduction <60%
Brink et al, 2004 [87] 13 AD
7 SCC
cis/5 FU 36 Gy/20# 2–3 weeks after CRT No correlation
Swisher et al, 2004 [88] 73 AD
10 SCC
See notes* 50.4 Gy/28# After CRT (not specified) Pathological response 
correlated with post 
therapy SUV. Post 
therapy SUV > 4 was 
only pre-operative 
factor to correlate with 
decreased survival
Wieder et al, 2004 [90] 38 SCC 5 FU 40 Gy/20# During CRT in 27 Changes in SUV were 
significantly different 
between 2 groups
Song et al, 2005 [89] 32 SCC cis/cape 45.6/38#(BID) + 46 Gy/23#/5 wks 4 weeks after CRT Pathological response 
could be predicted 
when analysis limited to 
initial highly metabolic 
tumours
Levine et al, 2006 [81] 52 AD
9 SCC
3 UN
cis/5 FU 50.4 Gy/28# After CRT (not specified) Reduction in SUV ≥ 10 
associated with 
significant response
Gillham et al, 2006 [91] 29 AD
3 SCC
cis/5 FU 40.05 Gy/15# 44 Gy/22# After 1 week of CRT Changes in SUV during 
treatment did not 
predict pathological 
outcome
Key: Path – histological sub-type, AD – adenocarcinoma, SCC – squamous cell carcinoma, UN – undifferentiated, CT – computed tomography, 5 FU – 5-
fluorouracil, Gy – Gray, # – fractions of radiotherapy, cis – cisplatin, LV – leucovorin, carbo – carboplatin, cape – capecitabine, gem – gemcitabine, BID – twice 
daily fractionation
‡ Received cisplatin/5 fluorouracil or cisplatin/taxol or carboplatin/5 fluorouracil in combination with radiotherapy
*Patients received either irinotecan/5 FU/docetaxol (up to 2 cycles) prior to CRT with same drugs (reduced dose) or same RT with cisplatin/5 FU 
or taxol/carboplatin (no pre-CRT chemotherapy)
World Journal of Surgical Oncology 2007, 5:97 http://www.wjso.com/content/5/1/97lead to the detection of stringently validated markers,
which become part of routine diagnostic work-up.
Molecular imaging is another evolving science. The cumu-
lative data suggests that changes seen on serial PET scans
after neo-adjuvant therapy correlate with the final patho-
logical response and survival. However larger numbers are
required and it would be more clinically beneficial if such
imaging proved predictive earlier in the course of treat-
ment.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
CG conceived the idea and wrote the manuscript.
JR and DH were involved in the drafting and final
approval of the manuscript
All authors read and approved the final manuscript.
References
1. MINDACT, (Microarray In Node negative Disease may
Avoid ChemoTherapy) (EORTC Protocol 10041 – BIG 3-04)
[http://www.eortc.be/services/unit/mindact/
MINDACT_websiteii.asp]. (Last accessed August 20, 2007)
2. Parkin DM: International variation.  Oncogene 2004,
23:6329-6340.
3. Iizuka T, Isono K, Kakegawa T, Watanabe H: Parameters linked to
ten-year survival in Japan of resected esophageal carcinoma.
Japanese Committee for Registration of Esophageal Carci-
noma Cases.  Chest 1989, 96:1005-1011.
4. Daly JM, Karnell LH, Menck HR: National cancer database report
on esophageal carcinoma.  Cancer 1996, 78:1820-1828.
5. Crew KD, Neugut AI: Epidemiology of upper gastrointestinal
malignancies.  Semin Oncol 2004, 31:450-464.
6. Enzinger PC, Mayer RJ: Esophageal Cancer.  N Engl J Med 2003,
349:2241-2252.
7. Altorki N, Kent M, Ferrara RN, Port J: Three-field lymph node
dissection for squamous cell and adenocarcinoma of the
esophagus.  Ann Surg 2002, 236:177-183.
8. Lerut T, Coosemans W, De Leyn P, Deneffe G, Topal B, Van de Ven
C, Van Raemdonck D: Reflections on 3-field lymphadenectomy
in carcinoma of the esophagus and gastroesophageal junc-
tion.  Hepato-Gastroenterology 1999, 46:717-725.
9. Suntharalingam M, Moughan J, Coia LR, Krasna MJ, Kachnic L, Haller
DG, Willett CG, John MJ, Minsky BD, Owen JB: The national prac-
tice for patients receiving radiation therapy for carcinoma of
the esophagus: Results of the 1996–1999 Patterns of Care
Study.  Cancer 1999, 85:2499-2505.
10. Geh JI, Crellin AM, Glynne-Jones R: Preoperative (neoadjuvant)
chemoradiotherapy in oesophageal cancer.  Br J Surg 2001,
88:338-356.
11. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Pet-
iot JF, Roussel A, Jacob JH, Segol P, Samama G, Ollivier J-M, Bonvalot
SB, Gignoux M: Pathologic assessment of tumor regression
after preoperative chemoradiotherapy of esophageal carci-
noma. Clinicopathologic correlations.  Cancer 1994,
73:2680-2686.
12. Swisher SG, Hofstetter W, Wu TT, Correa AM, Ajani JA, Komaki RR,
Chirieac L, Hunt KK, Liao Z, Phan A, Rice DC, Vaporciyan AA, Walsh
GL, Roth JA: Proposed revision of the esophageal cancer stag-
ing system to accommodate pathologic response (pPCR) fol-
lowing preoperative CRT (CRT).  Ann Surg 2005, 241:810-820.
13. Chirieac LR, Swisher SG, Ajani JA, Komaki RR, Correa AM, Morris JS,
Roth JA, Rashid A, Hamilton SR, Wu TT: Post therapy pathologic
stage predicts survival in patients with esophageal carci-
noma receiving preoperative CRT.  Cancer 2005,
103:1347-1355.
14. Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg
S: Randomized clinical trial of preoperative and postopera-
tive adjuvant chemotherapy with cisplatin, vindesine, and
bleomycin for carcinoma of the esophagus.  J Cardiovasc Surg
1988, 96(2):242-248.
15. Seitz JF, Perrier H, Monges G, Giovannini M, Gouvernet J: Multivar-
iate analysis of the prognostic factors of survival and the
response to treatment of squamous cell oesophageal cancer
by concomitant radiochemotherapy: Value of p53 immuno-
detection.  Gastroenterol Clin Biol 1995, 19:465-474.
16. Kitamura K, Kuwano H, Araki K, Egashira A, Kawaguchi H, Saeki H,
Morita M, Ohno S, Sugimachi K: Clinicopathologic features of
patients with oesophageal cancer obtaining histological
complete response for preoperative hyperthermo-chemo-
radiotherapy.  Int J Hyperthermia 1998, 14:233-243.
17. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM:
Accumulation of p53 protein correlates with a poor progno-
sis in human lung cancer.  Cancer Res 1992, 52:4828-4831.
18. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J, Carr
TW, Neal DE: p53 expression and clinical outcome in prostate
cancer.  Br J Urol 1993, 72:778-781.
19. Smith F, Reynolds J, Miller N, Stephens R, Kennedy M: Pathological
and molecular predictors of the response of rectal cancer to
neoadjuvant radiochemotherapy.  EJSO 2006, 32:55-64.
20. Ribeiro U Jr, Finkelstein SD, Safatle-Ribeiro AV, Landreneau RJ,
Clarke MR, Bakker A, Swalsky PA, Gooding WE, Posner MC: P53
sequence analysis predicts treatment response and outcome
of patients with esophageal carcinoma.  Cancer 1998, 83:7-18.
21. Lowe SW, Ruley HE, Jacks T, Houseman DE: P53-dependent apop-
tosis modulates the cytotoxicity of anticancer agents.  Cell
1993, 74:957-67.
22. Duhaylongsod FG, Gottfried MR, Iglehart JD, Vaughn AL, Wolfe WG:
The significance of c-erb B-2 and p53 immunoreactivity in
patients with adenocarcinoma of the esophagus.  Ann Surg
1995, 221:677-683.
23. Lam KY, Law S, Ma LT, Ong SK, Wong J: Pre-operative chemo-
therapy for squamous cell carcinoma of the oesophagus: Do
histological assessment and p53 over-expression predict
chemo-responsiveness?  Eur J Cancer 1997, 33:1221-1225.
24. Wynford-Thomas D: p53 in tumour pathology: can we trust
immunocytometry?  J Pathol 1992, 166:329-330.
25. Catalano V, Baldelli AM, Giordani P, Cascinu S: Molecular markers
predictive of response to chemotherapy in gastrointestinal
tumors.  Crit Rev Oncol Haematol 2001, 38:93-104.
26. el-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burrell
M, Hill DE, Healy E, Rees JL, Hamilton SR: Topological control of
p21WAF1/CIP1 expression in normal and neoplastic tissues.
Cancer Res 1995, 55:2910-2919.
27. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon
GJ: Radiation-induced cell cycle arrest compromized by p21
deficiency.  Nature 1995, 377:552-557.
28. Nakamura T, Hayashi K, Ota M, Ide H, Takasaki K, Mitsuhashi M:
Expression of p21(Waf1/Cip1) predicts response and survival
of esophageal cancer patients treated by chemoradiother-
apy.  Dis Oesophagus 2004, 17:315-321.
29. Nakashima S, Natsugoe S, Matsumoto M, Kijima F, Takebayashi Y,
Okumura H, Shimada M, Nakano S, Kusano C, Baba M, Takao S,
Aikou T: Expression of p53 and p21 is useful for the prediction
of preoperative chemotherapeutic effects in esophageal car-
cinoma.  Anticancer Res 2000, 20:1933-1937.
30. Okumura H, Natsugoe S, Matsumoto M, Mataki Y, Takatori H, Ishig-
ami S, Takao S, Aikou T: The predictive value of p53, p53R2, and
p21 for the effect of CRT therapy on oesophageal squamous
cell carcinoma.  Br J Cancer 2005, 92:284-289.
31. Rödel F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C,
Günther K, Schick C, Sauer R, Rödel C: High survivin expression
is associated with reduced apoptosis in rectal cancer and
may predict disease-free survival after preoperative radio-
chemotherapy and surgical resection.  Strahlenther Onkol 2002,
178:426-435.Page 9 of 11
(page number not for citation purposes)
World Journal of Surgical Oncology 2007, 5:97 http://www.wjso.com/content/5/1/9732. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui
A, Nishiwaki T, Moriyama S, Kudo J, Fujii Y: Expression of survivin
in esophageal cancer: correlation with the prognosis and
response to chemotherapy.  Int J Cancer 2001, 95:92-95.
33. Warnecke-Eberz U, Hokita S, Xi H, Higashi H, Baldus SE, Metzger R,
Brabender J, Bollschweiler E, Mueller RP, Dienes HP, Hoelscher AH,
Schneider PM: Overexpression of survivin mRNA is associated
with a favourable prognosis following neoadjuvant radioche-
motherapy in esophageal cancer.  Oncol Rep 2005,
13:1241-1246.
34. Lagarde SM, ten Kate FJ, Richel DJ, Offerhaus GJ, van Lanschot JJ:
Molecular prognostic factors in adenocarcinoma of the
esophagus and gastroesophageal junction.  Ann Surg Oncol 2007,
14:977-991.
35. Chen WC, McBride WH, Chen SM, Lee KF, Hwang TZ, Jung SM, Shau
H, Liao SK, Hong JH, Chen MF: Prediction of poor survival by
cyclooxygenase-2 in patients with T4 nasopharyngeal cancer
treated by radiation therapy: clinical and in vitro studies.
Head Neck 2005, 27:503-512.
36. Kim YB, Kim GE, Pyo HR, Cho NH, Keum KC, Lee CG, Seong J, Suh
CO, Park TK: Differential cyclooxygenase-2 expression in
squamous cell carcinoma and adenocarcinoma of the uter-
ine cervix.  Int J Radiat Oncol Biol Phys 2004, 60:822-829.
37. Takatori H, Natsugoe S, Okumura H, Matsumoto M, Uchikado Y,
Setoyama T, Sasaki K, Tamotsu K, Owaki T, Ishigami S, Aikou T:
Cyclooxygenase-2 expression is related to prognosis in
patients with esophageal squamous cell carcinoma.  Eur J Surg
Oncol 2007 in press.
38. Bhandari P, Bateman AC, Mehta RL, Stacey BS, Johnson P, Cree IA, Di
Nicolantonio F, Patel P: Prognostic significance of cyclooxygen-
ase-2 (COX-2) expression in patients with surgically resect-
able adenocarcinoma of the oesophagus.  BMC Cancer 2006,
6:134.
39. Vaupel P, Harrison L: Tumor hypoxia: causative factors, com-
pensatory mechanisms and cellular response.  Oncologist 2004,
9:4-9.
40. Weidner N: Intratumour micro vessel density as a prognostic
factor in cancer.  Am J Pathol 1995, 147:9-19.
41. Volm M, Rittgen W: Cellular predictive factors for the drug
response of lung cancer.  Anticancer Res 2000, 20:3449-3458.
42. Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, Nabeya
Y, Hayashi H, Takeda A, Shiratori T, Uno T, Ito H, Ochiai T: Expres-
sion of angiogenic factors predicts response to chemoradio-
therapy and prognosis of oesophageal squamous cell
carcinoma.  Br J Cancer 2002, 86:552-557.
43. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Sal-
loum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum
RR: Blockade of the vascular endothelial growth factor stress
response increases the anti-tumor effects of ionising radia-
tion.  Cancer Res 1999, 76:3374-3378.
44. Imdahl A, Bognar G, Schulte-Monting , Schoffel U, Farthmann EH,
Ihling C: Predictive factors for response to neoadjuvant ther-
apy in patients with oesophageal cancer.  Eur J Cardio-Thor Surg
2002, 21:657-663.
45. Hickey K, Grehan D, Reid IM, O'Briain S, Walsh TN, Hennessy TP:
Expression of epidermal growth factor receptor and prolif-
erating cell nuclear antigen predicts response of esophageal
squamous cell carcinoma to chemoradiotherapy.  Cancer
1994, 74:1693-1698.
46. Wang KL, Wu TT, Choi IS, Wang H, Reseetkova E, Correa AM, Hof-
stetter WL, Swisher SG, Ajani JA, Rashid A, Albarracin CT: Expres-
sion of epidermal growth factor receptor in esophageal and
esophagogastric junction adenocarcinomas: association with
poor outcome.  Cancer 2007, 109:658-667.
47. Wright C, Angus B, Nicholson S, Sainsbury JR, Cairns J, Gullick WJ,
Kelly P, Harris AL, Horne CH: Expression of c-erbB-2 oncopro-
tein: a prognostic indicator in human breast cancer.  Cancer
Res 1989, 49:2087-2090.
48. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS: HER-2/neu
gene amplification by FISH predicts poor survival in Bar-
rett's esophagus-associated adenocarcinoma.  Hum Pathol
2000, 31:35-39.
49. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama
Y, Tsurumaru M, Sasai K: c-erb B-2 oncoprotein expression
related to chemoradioresistance in esophageal squamous
cell carcinoma.  Int J Radiation Oncol Biol Phys 2003, 57:1323-1327.
50. Sarbia M, Stahl M, Fink U, Heep H, Dutkowski P, Willers R, Seeber S,
Gabbert HE: Prognostic significance of cyclin D1 in esophageal
squamous cell carcinoma patients treated with surgery
alone or combined therapy modalities.  Int J Cancer 1999,
84:86-91.
51. Tenderenda M: A study on the prognostic value of cyclins D1
and E expression levels in respectable gastric cancer and on
some correlations between cyclins expression, histoclinical
parameters and selected protein products of cell-cycle regu-
latory genes.  J Exp Clin Cancer Res 2005, 24:405-414.
52. Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Hern-
don JE, Danenberg PV, Harpole DH: High gene expression of
TS1, GSTP1, and ERCC1 are risk factors for survival in
patients treated with trimodality therapy for esophageal
cancer.  Clin Cancer Res 2005, 11:2215-2221.
53. Janssen AM, van Duijn W, Kubben FJ, Griffioen G, Lamers CB, van
Krieken JH, van de Velde CJ, Verspaget HW: Prognostic signifi-
cance of metallothionein in human gastrointestinal cancer.
Clin Cancer Res 2002, 8:1889-1896.
54. Kishi K, Doki Y, Miyata H, Yano M, Yasuda T, Monden M: Prediction
of the response to CRT and prognosis in oesophageal squa-
mous cancer.  Br J Surg 2002, 89:597-603.
55. Harpole DH Jr, Moore MB, Herndon JE 2nd, Aloia T, D'Amico TA,
Sporn T, Parr A, Linoila I, Allegra C: The prognostic value of
molecular marker analysis in patients treated with trimodal-
ity therapy for esophageal cancer.  Clin Cancer Res 2001,
7:562-569.
56. Li Y, Wo JM, Cai L, Zhou Z, Rosenbaum D, Mendez C, Ray MB, Jones
WF, Kang YJ: Association of metallothionein expression and
lack of apoptosis with progression of carcinogenesis in Bar-
rett's esophagus.  Exp Biol Med 2003, 228(3):286-292.
57. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher
D, Reynolds JV: NF-kappa B activation in esophageal adeno-
carcinoma: relationship to Barrett's metaplasia, survival,
and response to neoadjuvant chemoradiotherapy.  Ann Surg
2004, 239:491-500.
58. Izzo JG, Correa AM, Wu TT, Malhotra U, Chao CK, Luthra R, Ensor
J, Dekovich A, Liao Z, Hittelman WN, Aggarwal BB, Ajani JA: Pre-
therapy nuclear factor-kappa B status, chemoradiation
resistance, and metastatic progression in esophageal carci-
noma.  Mol Cancer Ther 2006, 5:2844-2850.
59. Kim YH, Ajani JA, Ota DM, Lynch P, Roth JA: Value of serial carci-
noembryonic antigen levels in patients with resectable ade-
nocarcinoma of the esophagus and stomach.  Cancer 1995,
75:451-456.
60. McDonnell CO, Harmey JH, Bouchier-Hayes DJ, Walsh TN: Effect
of multimodality therapy on circulating vascular endothelial
growth factor levels in patients with esophageal cancer.  Br J
Surg 2001, 88:1105-1109.
61. Quillien V, Raoul JL, Laurent JF, Meunier B, Le Prise E: Comparison
of cyfra 21-1, TPA and SCC tumor markers in esophageal
squamous cell carcinoma.  Oncol Rep 1998, 5:1561-1565.
62. Nakamura T, Ide H, Eguchi R, Hayashi K, Takasaki K, Watanabe S:
CYFRA 21-1 as a tumour marker for squamous cell carci-
noma of the esophagus.  Dis Esophagus 1998, 11:35-39.
63. Schmidt U, Begley CG: Cancer diagnosis and microarrays.  Int J
Biochem Cell Biol 2003, 35:119-124.
64. Xu Y, Selaru FM, Yin J, Zou TT, Shustova V, Mori Y, Sato F, Liu TC,
Olaru A, Wang S, Kimos MC, Perry K, Desai K, Greenwald BD, Kra-
sna MJ, Shibata D, Abraham JM, Meltzer SJ: Artificial neural net-
works and gene filtering distinguish between global gene
expression profiles of Barrett's esophagus and esophageal
cancer.  Cancer Res 2002, 62:3493-3497.
65. Dahlberg PS, Ferrin LF, Grindle SM, Nelson CM, Hoang CD, Jacobson
B: Gene expression profiles in esophageal adenocarcinoma.
Ann Thorac Surg 2004, 77:1008-1015.
66. McManus DT, Olaru A, Meltzer SJ: Biomarkers of esophageal
adenocarcinoma and Barrett's esophagus.  Cancer Res 2004,
64:1561-1569.
67. Lu J, Liu Z, Xiong M, Wang Q, Wang X, Yang G, Zhao L, Qiu Z, Zhou
C, Wu M: Gene expression profile changes in initiation and
progression of squamous cell carcinoma of esophagus.  Int J
Cancer 2001, 91:288-294.
68. Xu SH, Qian LJ, Mou HZ, Zhu CH, Zhou XM, Liu XL, Chen Y, Bao
WY: Difference of gene expression profiles between esopha-Page 10 of 11
(page number not for citation purposes)
World Journal of Surgical Oncology 2007, 5:97 http://www.wjso.com/content/5/1/97geal carcinoma and its precancerous epithelium by gene
chip.  World J Gastroenterol 2003, 9:417-422.
69. Su H, Hu N, Shih J, Hu Y, Wang QH, Chuang EY, Roth MJ, Wang C,
Goldstein AM, Ding T, Dawsey SM, Giffen C, Emmert-Buck MR, Tay-
lor PR: Gene expression analysis of esophageal squamous cell
carcinoma reveals consistent molecular profiles related to a
family history of upper gastrointestinal cancer.  Cancer Res
2003, 63:3872-3876.
70. Kawamata H, Furihata T, Omotehara F, Sakai T, Horiuchi H, Shina-
gawa Y, Imura J, Ohkura Y, Tachibana M, Kubota K, Terano A, Fuji-
mori T: Identification of genes differentially expressed in a
newly isolated human metastasizing esophageal cancer cell
line, T.Tn-AT1, by cDNA microarray.  Cancer Sci 2003,
94:699-706.
71. Luthra R, Wu TT, Luthra MG, Izzo J, Lopez-Alvarez E, Zhang L, Bailey
J, Lee JH, Bresalier R, Rashid A, Swisher SG, Ajani JA: Gene expres-
sion profiling of localized esophageal carcinomas: associa-
tion with pathologic response to preoperative CRT.  J Clin
Oncol 2006, 24:259-267.
72. Agarwal B, Swisher S, Ajani J, Kelly K, Fanning C, Komaki RR, Putnam
JB Jr, Abu-Hamda E, Molke KL, Walsh GL, Correa AM, Ho L, Liao Z,
Lynch PM, Rice DC, Smythe WR, Stevens CW, Vaporciyan AA, Yao
J, Roth JA: Endoscopic ultrasound after preoperative chemo-
radiation can help identify patients who benefit maximally
after surgical esophageal resection.  Am J Gastroenterol 2004,
99:1258-1266.
73. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R,
Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR,
Vaporciyan AA, Walsh GL, Wu TT, Roth JA: Utility of PET, CT
and EUS to identify pathologic responders in esophageal
cancer.  Ann Thorac Surg 2004, 78:1152-1160.
74. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Deh-
dashti F, Siegel BA, Cooper JD: Improvement in staging of
esophageal cancer with the addition of positron emission
tomography.  Ann Thorac Surg 1997, 64:770-776.
75. Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroo-
bants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck
D, Coosemans W, Ectors N, Haustermans K, Mortelmans L: Utility
of positron emission tomography for the staging of patients
with potentially operable esophageal carcinoma.  J Clin Oncol
2000, 18:3202-3210.
76. Schelling M, Avril N, Nährig J, Kuhn W, Römer W, Sattler D, Werner
M, Dose J, Jänicke F, Graeff H, Schwaiger M: Positron emission
tomography using [18(F)] fluorodeoxyglucose for monitor-
ing primary chemotherapy in breast cancer.  J Clin Oncol 2000,
18:1689-1695.
77. Thomas DM, Mitchell PL, Berlangieri SU, Tochon-Danguy H, Knight
S, Clarke CP, Scott AM: The role of positron emission tomog-
raphy in assessing response to neoadjuvant chemotherapy
for non-small cell lung cancer.  Med J Aust 1998, 169:227. Erra-
tum in Med J Aust 1998;169:344
78. Yoshioka T, Fukuda H, Fujiwara T, Iwata R, Ido T, Murakawa Y, Gamo
M, Ishioka C, Kanamaru R: FDG PET evaluation of residual
masses and regrowth of abdominal lymph node metastases
from colon cancer compared with CT during chemotherapy.
Clin Nucl Med 1999, 24:261-263.
79. Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mer-
genthaler HG, Bihl H: Whole body positron emission tomogra-
phy in the treatment of Hodgkin disease.  Cancer 2001,
91:302-310.
80. Okada J, Yoshikawa K, Imazeki K, Minoshima S, Uno K, Itami J,
Kuyama J, Maruno H, Arimizu N: The use of FDG-PET in the
detection and management of malignant lymphoma: corre-
lation of uptake with prognosis.  J Nucl Med 1991, 32:686-691.
81. Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin
SA, Lovato J, Oaks T, Blackstock AW: Predictive value of 18 FDG-
PET in the identification of responders to chemoradiation
therapy for the treatment of locally advanced esophageal
cancer.  Ann Surg 2006, 243:472-478.
82. Brücher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner
M, Zimmerman F, Siewert JR, Schwaiger M: Neoadjuvant therapy
of esophageal squamous cell carcinoma: Response evalua-
tion by positron emission tomography.  Ann Surg 2001,
233:300-309.
83. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda
N, Fukuchi M, Manda R, Tsukada K, Oriuchi N, Endo K: Usefulness
of positron emission tomography for assessing the response
of neoadjuvant chemoradiotherapy in patients with
oesophageal cancer.  Am Surg 2002, 184:279-283.
84. Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA: Evalua-
tion of response to neoadjuvant therapy by quantitative 2-
deoxy-2-[18F]Fluoro-D-Glucose with positron emission
tomography in patients with esophageal cancer.  Mol Imag Biol
2002, 4:301-310.
85. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bor-
mans G, De Leyn P, Van Raemdonck D, De Wever W, Ectors N, Maes
A, Mortelmans L: Positron emission tomography for assess-
ment of the response to induction radiochemotherapy in
locally advanced esophageal cancer.  Ann Oncol 2002,
13:361-368.
86. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M,
Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, Larson SM,
Rusch V: Whole body FDG-PET and the response of esopha-
geal cancer to induction therapy: Results of a prospective
trial.  J Clin Oncol 2003, 21:428-432.
87. Brink I, Hentschel M, Bley TA, Walch A, Mix M, Kleimaier M, Moser
E, Imdahl A: Effects of neoadjuvant radio-chemotherapy on
18F-FDG-PET in esophageal carcinoma.  Eur J Surg Oncol 2004,
30:544-550.
88. Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA,
Cox JD, Komaki RR, Hong D, Lee HK, Putnam JB Jr, Rice DC, Smythe
WR, Thai L, Vaporciyan AA, Walsh GL, Wu TT, Roth JA: 2-Fluoro-
2-deoxy-D-glucose positron emission tomography imaging is
predictive of pathologic response and survival after preoper-
ative CRT in patients with esophageal carcinoma.  Cancer
2004, 101:1776-1785.
89. Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song HY, Cho KJ,
Ahn SD, Lee SW, Shin SS, Choi EK: FDG-PET in the prediction of
pathologic response after neoadjuvant chemoradiotherapy
in locally advanced, resectable esophageal cancer.  IJROBP
2005, 63(4):1053-1059.
90. Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer
A, Schwaiger M, Fink U, Siewert JR, Stein HJ, Weber WA: Time
course of tumor metabolic activity during chemoradiother-
apy of esophageal squamous cell carcinoma and response to
treatment.  J Clin Oncol 2004, 22:900-908.
91. Gillham Charles M, Lucey Julie A, Keogan Mary, Duffy George J, Malik
Vinod, Raouf Ali A, O'Byrne Ken, Hollywood Donal, Muldoon Cian,
Reynolds John V: Correlation of Early Quantitative changes in
FDG-PET Uptake with Tumour Regression grade in patients
with Localized Oesophageal cancer undergoing Neo-adju-
vant Chemoradiation.  Br J Cancer 2006, 95:1174-1179.
92. Grube D: Constants and variables in immunohistochemistry.
Arch Histol Cytol 2004, 67:115-134.
93. Bast RC Jr, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA,
Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K:
New tumor markers: CA125 and beyond.  Int J Gynecol Cancer
2005, 15(Suppl 3):274-281.
94. Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA,
Heinz DE, Shroyer KR, Duncan MW, Haugen BR: Quantitative and
qualitative differences in protein expression between papil-
lary thyroid carcinoma and normal thyroid tissue.  Mol Car-
cinog 2006, 45:613-626.
95. Feldman AL, Espina V, Petricoin EF, Liotta LA, Rosenblatt KP: Use of
proteomic patterns to screen for gastrointestinal malignan-
cies.  Surgery 2004, 135:243-248.Page 11 of 11
(page number not for citation purposes)
